Le Lézard
Classified in: Health
Subject: SLS

Alafair Biosciences Announces VersaWrap® Sales Milestone


AUSTIN, Texas, Oct. 4, 2022 /PRNewswire/ -- Alafair Biosciences, Inc., a commercial-stage medical device company, announced that sales of its flagship product, VersaWrap®, have now exceeded 5000 units since commercial launch. This sales growth reflects expanding surgeon adoption and clinical need for VersaWrap. VersaWrap is an ultrathin, sutureless, bioresorbable hydrogel implant that manages tendons, ligament, skeletal muscle, and peripheral nerve tissues. Forming a permeable, gelatinous layer around target tissues, VersaWrap facilitates improved tissue gliding during healing. This thin layer reduces surface-to-surface friction, leading to reduced postoperative tethering.

"VersaWrap is a great option for my patients that are prone to scarring," stated Dr. Adam Strohl, MD, hand surgeon in Philadelphia, PA. "We've applied VersaWrap in both complex and straightforward cases, and there is a noticeable difference in the recovery of these patients. They report a faster return to life with less therapy. We are looking forward to seeing the results of our upcoming study."

VersaWrap's commercial success allows expansion of marketing initiatives and the pursuit of additional markets. "VersaWrap adoption consistently exceeds our expectations," said John Joyoprayitno, Alafair Chief Executive Officer. "This growth trajectory is owed to not only the device composition and its ability to provide a gliding surface, but also to the creativity of physicians in finding new and exciting applications for VersaWrap."

Launched in December 2017, VersaWrap has experienced rapid market adoption in diverse clinical procedures. Alafair anticipates additional 510(k) filings next year as it seeks to expand the clinical applications for the use of its hydrogel technology.

About Alafair Biosciences, Inc. (www.alafairbiosciences.com)

Alafair is privately-held, developing animal/human tissue-free medical devices based on its proprietary technology with a portfolio of 28 issued and 8 pending patents. Alafair products are distributed through a dispersed network of independent distributors across the United States.

SOURCE Alafair Biosciences, Inc.


These press releases may also interest you

at 18:30
Baltimore Urban Gardening with Students (BUGS), a program operated by The Crossroads School, a Living Classrooms Foundation Charter School, is excited to announce its 26th Annual Youth Farmer's Market taking place on Saturday, May 18th, from 9:00 AM...

at 18:15
DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units...

at 18:07
A new guideline has been issued to help neurologists and other clinicians determine the best antiseizure medications for people with epilepsy who may become pregnant. The guideline is published in the May 15, 2024, online issue of Neurology®, the...

at 18:00
The leading cause of death worldwide is chronic inflammatory diseases. When the body is inflamed and under stress for long periods of time, the body's heart rate increases, increasing the risk of fatality. A new study published in Brain, Behavior and...

at 17:55
The global gas chromatography market  size is estimated to grow by USD 1042.59 mn from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of  7.14%  during the forecast period. ...

at 17:50
Blue Cross Blue Shield of Michigan's Board of Directors today appointed Tricia A. Keith as president and CEO-Elect. Ms. Keith, 53, will succeed Daniel J. Loepp as president and CEO following his retirement on January 1, 2025. She will become the...



News published on and distributed by: